![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BIO Says BsUFA II Appraisal Must Include Third-Party Evaluator
BIO Says BsUFA II Appraisal Must Include Third-Party Evaluator
August 2, 2017
A third-party evaluator should be used to assess the expanded communications program proposed in the next generation of the FDA’s biosimilar user fees, according to BIO.
The agency is proposing a new model for reviewing 351(k) applications, including more time for communication between review teams and sponsors through development meetings during submissions.
In a comment on the draft proposal, BIO said it agrees with the agency’s underlying aim of extending the transparency measures established under PDUFA to biosimilars, but said a third-party evaluation of whether the program achieved its goals is vital to its success.
Upcoming Events
-
21Oct